Identification of Attractive Drug Targets in Neglected-Disease Pathogens Using an In Silico Approach

Background The increased sequencing of pathogen genomes and the subsequent availability of genome-scale functional datasets are expected to guide the experimental work necessary for target-based drug discovery. However, a major bottleneck in this has been the difficulty of capturing and integrating relevant information in an easily accessible format for identifying and prioritizing potential targets. The open-access resource TDRtargets.org facilitates drug target prioritization for major tropical disease pathogens such as the mycobacteria Mycobacterium leprae and Mycobacterium tuberculosis; the kinetoplastid protozoans Leishmania major, Trypanosoma brucei, and Trypanosoma cruzi; the apicomplexan protozoans Plasmodium falciparum, Plasmodium vivax, and Toxoplasma gondii; and the helminths Brugia malayi and Schistosoma mansoni. Methodology/Principal Findings Here we present strategies to prioritize pathogen proteins based on whether their properties meet criteria considered desirable in a drug target. These criteria are based upon both sequence-derived information (e.g., molecular mass) and functional data on expression, essentiality, phenotypes, metabolic pathways, assayability, and druggability. This approach also highlights the fact that data for many relevant criteria are lacking in less-studied pathogens (e.g., helminths), and we demonstrate how this can be partially overcome by mapping data from homologous genes in well-studied organisms. We also show how individual users can easily upload external datasets and integrate them with existing data in TDRtargets.org to generate highly customized ranked lists of potential targets. Conclusions/Significance Using the datasets and the tools available in TDRtargets.org, we have generated illustrative lists of potential drug targets in seven tropical disease pathogens. While these lists are broadly consistent with the research community's current interest in certain specific proteins, and suggest novel target candidates that may merit further study, the lists can easily be modified in a user-specific manner, either by adjusting the weights for chosen criteria or by changing the criteria that are included.

[1]  A. Vaughan,et al.  Type II fatty acid synthesis is essential only for malaria parasite late liver stage development , 2008, Cellular microbiology.

[2]  F. Joubert,et al.  Structure‐based inhibitor screening: A family of sulfonated dye inhibitors for malaria parasite triosephosphate isomerase , 2001, Proteins.

[3]  I. Fairweather,et al.  A possible model of benzimidazole binding to beta-tubulin disclosed by invoking an inter-domain movement. , 2004, Journal of molecular graphics & modelling.

[4]  Jason A. Papin,et al.  Systems analysis of metabolism in the pathogenic trypanosomatid Leishmania major , 2008, Molecular systems biology.

[5]  Haiming Wang,et al.  SchistoDB: a Schistosoma mansoni genome resource , 2008, Nucleic Acids Res..

[6]  G. Mustata,et al.  A Target-Based High Throughput Screen Yields Trypanosoma brucei Hexokinase Small Molecule Inhibitors with Antiparasitic Activity , 2010, PLoS neglected tropical diseases.

[7]  David Osumi-Sutherland,et al.  FlyBase: enhancing Drosophila Gene Ontology annotations , 2008, Nucleic Acids Res..

[8]  Patricia De la Vega,et al.  Discovery of Gene Function by Expression Profiling of the Malaria Parasite Life Cycle , 2003, Science.

[9]  Richard J. Marhöfer,et al.  A Comparative Chemogenomics Strategy to Predict Potential Drug Targets in the Metazoan Pathogen, Schistosoma mansoni , 2009, PloS one.

[10]  Karl W. Broman,et al.  A postgenomic method for predicting essential genes at subsaturation levels of mutagenesis: Application to Mycobacterium tuberculosis , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[11]  M. Lynch,et al.  The altered evolutionary trajectories of gene duplicates. , 2004, Trends in genetics : TIG.

[12]  Manoj Kumar,et al.  Structure‐Based Design of a Novel Class of Potent Inhibitors of InhA, the Enoyl Acyl Carrier Protein Reductase from Mycobacterium Tuberculosis: A Computer Modelling Approach , 2008, Chemical biology & drug design.

[13]  I. Coppens,et al.  The adaptative mechanisms of Trypanosoma brucei for sterol homeostasis in its different life-cycle environments. , 2000, Annual review of microbiology.

[14]  P. Michels,et al.  Genetic validation of aldolase and glyceraldehyde-3-phosphate dehydrogenase as drug targets in Trypanosoma brucei. , 2010, Molecular and biochemical parasitology.

[15]  Wim G J Hol,et al.  Heterologous expression of proteins from Plasmodium falciparum: results from 1000 genes. , 2006, Molecular and biochemical parasitology.

[16]  E. Rubin,et al.  Genome-wide requirements for Mycobacterium tuberculosis adaptation and survival in macrophages. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[17]  Marc A. Martí-Renom,et al.  MODBASE: a database of annotated comparative protein structure models and associated resources , 2005, Nucleic Acids Res..

[18]  Eileen Kraemer,et al.  TriTrypDB: a functional genomic resource for the Trypanosomatidae , 2009, Nucleic Acids Res..

[19]  Xinxia Peng,et al.  A combined transcriptome and proteome survey of malaria parasite liver stages , 2008, Proceedings of the National Academy of Sciences.

[20]  John P. Overington,et al.  Genomic-scale prioritization of drug targets: the TDR Targets database , 2008, Nature Reviews Drug Discovery.

[21]  Antje Chang,et al.  BRENDA, AMENDA and FRENDA the enzyme information system: new content and tools in 2009 , 2008, Nucleic Acids Res..

[22]  R. Altman,et al.  Drug Targets for Plasmodium falciparum: a post-genomic review/survey. , 2006, Mini reviews in medicinal chemistry.

[23]  Christopher M. Sassetti,et al.  Genetic requirements for mycobacterial survival during infection , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[24]  P. Overath,et al.  The molecular phylogeny of trypanosomes: evidence for an early divergence of the Salivaria. , 1998, Molecular and biochemical parasitology.

[25]  T. Jones,et al.  Structural basis for the inhibition of Mycobacterium tuberculosis glutamine synthetase by novel ATP-competitive inhibitors. , 2009, Journal of molecular biology.

[26]  全忠 林,et al.  Trypanosoma cruzi , 1937, CABI Compendium.

[27]  A. Hopkins,et al.  The druggable genome , 2002, Nature Reviews Drug Discovery.

[28]  J. Bennett,et al.  Physiological role of HMG-CoA reductase in regulating egg production by Schistosoma mansoni. , 1989, The American journal of physiology.

[29]  F. Opperdoes,et al.  The Trypanosoma cruzi Proteome , 2005, Science.

[30]  Midori Kato-Maeda,et al.  Functional and evolutionary genomics of Mycobacterium tuberculosis: insights from genomic deletions in 100 strains. , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[31]  P. Michels,et al.  Molecular and biochemical characterization of novel glucokinases from Trypanosoma cruzi and Leishmania spp. , 2007, Molecular and biochemical parasitology.

[32]  Philip E. Bourne,et al.  The RCSB PDB information portal for structural genomics , 2005, Nucleic Acids Res..

[33]  Sharmila Anishetty,et al.  Potential drug targets in Mycobacterium tuberculosis through metabolic pathway analysis , 2005, Comput. Biol. Chem..

[34]  Wendy A. Warr,et al.  ChEMBL. An interview with John Overington, team leader, chemogenomics at the European Bioinformatics Institute Outstation of the European Molecular Biology Laboratory (EMBL-EBI) , 2009, J. Comput. Aided Mol. Des..

[35]  Meena Kishore Sakharkar,et al.  A novel genomics approach for the identification of drug targets in pathogens, with special reference to Pseudomonas aeruginosa , 2004, Silico Biol..

[36]  James R. Brown,et al.  Identification of gene targets against dormant phase Mycobacterium tuberculosis infections , 2007, BMC infectious diseases.

[37]  L. Holden-Dye,et al.  SLO, SLO, quick, quick, slow: calcium-activated potassium channels as regulators of Caenorhabditis elegans behaviour and targets for anthelmintics , 2007, Invertebrate Neuroscience.

[38]  E. Rubin,et al.  Transposon site hybridization in Mycobacterium tuberculosis. , 2008, Methods in molecular biology.

[39]  R. Pax,et al.  Na+–K+ transport, motility and tegumental membrane potential in adult male Schistosoma mansoni , 1981, Parasitology.

[40]  J. Vermunt,et al.  Assessing Performance of Orthology Detection Strategies Applied to Eukaryotic Genomes , 2007, PloS one.

[41]  N. Surolia,et al.  Design, development, synthesis, and docking analysis of 2′‐substituted triclosan analogs as inhibitors for Plasmodium falciparum Enoyl‐ACP reductase , 2009, IUBMB life.

[42]  G. H. Coombs,et al.  Two pathways for cysteine biosynthesis in Leishmania major. , 2009, The Biochemical journal.

[43]  Christopher J. Tonkin,et al.  Dissecting Apicoplast Targeting in the Malaria Parasite Plasmodium falciparum , 2003, Science.

[44]  J. Foster,et al.  Mining Predicted Essential Genes of Brugia malayi for Nematode Drug Targets , 2007, PloS one.

[45]  R. Martin,et al.  Modes of action of anthelmintic drugs. , 1997, Veterinary journal.

[46]  F. Buckner,et al.  Crystal structures of trypanosomal histidyl-tRNA synthetase illuminate differences between eukaryotic and prokaryotic homologs. , 2010, Journal of molecular biology.

[47]  Christopher J. Tonkin,et al.  Protein Targeting to the Malaria Parasite Plastid , 2007, Traffic.

[48]  John P. Overington,et al.  The genome of the blood fluke Schistosoma mansoni , 2009, Nature.

[49]  H. Hwang,et al.  Genetic Analysis of Purine Metabolism in Leishmania donovani * , 1997, The Journal of Biological Chemistry.

[50]  Ross S Hall,et al.  Drug target prediction and prioritization: using orthology to predict essentiality in parasite genomes , 2010, BMC Genomics.

[51]  Feng Chen,et al.  OrthoMCL-DB: querying a comprehensive multi-species collection of ortholog groups , 2005, Nucleic Acids Res..

[52]  Samiul Hasan,et al.  Prioritizing Genomic Drug Targets in Pathogens: Application to Mycobacterium tuberculosis , 2006, PLoS Comput. Biol..

[53]  John P. Overington ChEMBL. An interview with John Overington, team leader, chemogenomics at the European Bioinformatics Institute Outstation of the European Molecular Biology Laboratory (EMBL-EBI). Interview by Wendy A. Warr. , 2009, Journal of computer-aided molecular design.

[54]  E. Rubin,et al.  Genes required for mycobacterial growth defined by high density mutagenesis , 2003, Molecular microbiology.

[55]  L. A. Basso,et al.  One-step purification of 5-enolpyruvylshikimate-3-phosphate synthase enzyme from Mycobacterium tuberculosis. , 2003, Protein expression and purification.

[56]  Barbara M. Bakker,et al.  Experimental and in Silico Analyses of Glycolytic Flux Control in Bloodstream Form Trypanosoma brucei* , 2005, Journal of Biological Chemistry.

[57]  Dhilon S. Patel,et al.  Shape‐ and Chemical Feature‐Based 3D‐Pharmacophore Model Generation and Virtual Screening: Identification of Potential Leads for P. falciparum DHFR Enzyme Inhibition , 2010, Chemical biology & drug design.

[58]  Alok Bhattacharya,et al.  Inhibitors of Escherichia coli serine acetyltransferase block proliferation of Entamoeba histolytica trophozoites. , 2008, International journal for parasitology.

[59]  Eileen Kraemer,et al.  PlasmoDB: a functional genomic database for malaria parasites , 2008, Nucleic Acids Res..

[60]  Solomon Nwaka,et al.  Innovative lead discovery strategies for tropical diseases , 2006, Nature Reviews Drug Discovery.

[61]  Kalidas Yeturu,et al.  targetTB: A target identification pipeline for Mycobacterium tuberculosis through an interactome, reactome and genome-scale structural analysis , 2008, BMC Systems Biology.

[62]  M. Mather,et al.  Mitochondrial drug targets in apicomplexan parasites. , 2007, Current drug targets.

[63]  P. Selzer,et al.  A combined bioinformatics and chemoinformatics approach for the development of new antiparasitic drugs. , 2007, Genomics.